Novel Aspects of Follistatin/Transforming Growth Factor-β (TGF-β) Signaling in Adipose Tissue Metabolism: Implications in Metabolic Health by Pervin, Shehla et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Novel Aspects of Follistatin/
Transforming Growth Factor-β 
(TGF-β) Signaling in Adipose 
Tissue Metabolism: Implications in 
Metabolic Health
Shehla Pervin, Wilson Nyah, Srinivasa T. Reddy  
and Rajan Singh
Abstract
Obesity is a major risk factor for several metabolic disorders including insulin 
resistance, diabetes, and cardiovascular diseases. Chronic imbalance of calorie 
intake and expenditure results in storage of excess unused energy resulting in 
obesity and related metabolic dysfunctions. While most obesity therapies are 
focused on reducing the calorie intake and exercise, recent studies suggest that 
targeting cellular energy expenditure could be a fascinating alternative approach. 
Brown adipose tissue (BAT) not only has a remarkable calorie burning capacity, 
but it could also promote triglyceride clearance and glucose disposal. Induction of 
brown adipose mass and activity in relevant tissues are linked to relieve symptoms 
of various metabolic disorders such as diabetes, insulin resistance, and cardiovas-
cular diseases. Follistatin (Fst), an extracellular protein that binds and antagonizes 
several members of the transforming growth factor beta (TGF-β)/myostatin (Mst) 
superfamily, promotes brown adipose characteristics in both white and brown 
adipose tissues by targeting distinct molecular pathways. Inhibition of Mst, on the 
other hand, leads to significant upregulation of adipose browning in white adipose 
tissues. This chapter will summarize most recent developments in targeting adipose 
tissue and their functional characteristics to explore therapeutic potential of Fst 
and TGF-β/Mst signaling to modulate adipose tissue metabolic functions to combat 
obesity and related metabolic syndromes.
Keywords: adipocyte, follistatin, myostatin, transforming growth factor beta, 
adipose browning, uncoupling protein 1, thermogenesis, insulin sensitivity
1. Introduction
Obesity is a global health problem that results from chronic imbalance between 
energy intake and its expenditure. Obesity is a major risk factor for several meta-
bolic diseases including diabetes, dyslipidemia, insulin resistance, cardiovascular 
diseases, nonalcoholic fatty liver, and even some form of cancer. According to most 
recent global estimates, by year 2030 roughly 2.16 billion individuals will be obese 
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as defined by body mass index (BMI) of 30 or higher [1]. The economic impact of 
obesity and related metabolic complications has been estimated between 4 and 8% 
of gross domestic product which is comparable to 2018 defense budget ($643 billion) 
and Medicare ($588 billion) in the United States [2]. Thus the toll of obesity imposes 
massive and rapidly growing economic cost beyond human suffering. This economic 
burden of obesity, therefore, significantly impacts low-income and otherwise 
disadvantaged population. Staying physically active and maintaining a healthy diet 
are well accepted and proven strategies to prevent weight gain; however, an alarming 
increase of global obesity urgently requires the development of novel and highly 
effective anti-obesity therapies. According to the laws of thermodynamics, any 
treatment for obesity must require reduced energy intake, increased energy expen-
diture, or both. Recent data suggest that targeting cellular bioenergetics may provide 
attractive therapeutic avenues for the treatment and prevention of obesity. White 
adipose tissue (WAT) and brown adipose tissue (BAT) are two distinct adipose tissue 
types present in mammals. While WAT with larger unilocular lipid droplets store 
excess energy in the form of triglycerides, BAT consisting of multilocular smaller 
lipid droplets enriched with mitochondria that express uncoupling protein 1 (UCP1) 
has specialized capacity to dissipate excess energy via activating non-shivering ther-
mogenesis. Pockets of UCP1-positive adipocytes have also been found within WAT 
depots which are called beige or brite (brown within white) adipocytes. These beige 
adipocytes show some morphological and functional similarities to classical brown 
adipocytes present with the BAT. Several molecular signaling pathways are reported 
to play significant roles in the development and differentiation of these white, beige, 
and brown adipose cells. Transforming growth factor beta (TGF-β) controls the 
development, growth, and cellular functions of diverse cell types by transmitting 
signals via dual serine/threonine kinase receptors and transcription factors called 
Smads, especially Smad3. TGF-β expression levels are significantly elevated in 
adipose tissues from obese mice [3], and blocking of TGF-β/Smad3 signaling results 
in protection from obesity and diabetes. These metabolic benefits are associated with 
increased appearance of brown-like adipocytes within the WAT [4]. Inactivation 
of myostatin (Mst) also called growth and differentiation factor 8 (GDF8), a key 
member of the TGF-β superfamily in both differentiating mouse embryonic fibro-
blast (MEF) primary cultures from wild type (WT) and Mst knockout (Mst KO) 
embryos, as well as in white adipose tissues of Mst KO mouse models, displays beige 
adipocyte phenotype and upregulation of key beige markers compared to the wild 
type [5]. Blockade of activin receptor IIB (ActRIIB) that integrates the actions of 
Mst and TGF-β-related ligands has been demonstrated to activate functional brown 
adipogenesis and thermogenesis [6]. Inhibition of Smad3 signaling, which has been 
identified as canonical pathway for Mst, induced WAT browning [7]. It therefore 
suggests that antagonizing TGF-β/Smad3/Mst signaling pathway would lead to 
significant favorable metabolic alterations by promoting adipose browning. Since 
follistatin (Fst) is a well-known inhibitor of TGF-β signaling pathway in a variety of 
cell lines [8–10], and a key antagonist of Mst, Braga et al. [11] hypothesized that Fst 
may promote browning of white adipocytes, and using differentiating MEF primary 
cultures from WT and Fst KO embryos provided the first evidence that Fst is a novel 
inducer of brown adipose characteristics. Subsequent studies using Fst-transgenic 
(Fst-Tg) mice overexpressing Fst under the control of skeletal muscle-specific myo-
sin light chain promoter, the authors demonstrated that Fst targets distinct pathways 
to promote brown adipose characteristics in both BAT and WAT [11]. Combined 
together, these findings support the idea that targeting TGF-β/Smad3/Mst signal-
ing either via direct genetic or pharmacological inhibition of this pathways or via 
directly upregulating Fst could be attractive therapeutic options for the treatment of 
obesity and related metabolic diseases.
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2.  Developmental origin, transcriptional regulators, and molecular 
signature of beige and brown adipocytes
Although white and brown adipocytes share many common features such as 
PPAR-γ-driven transcriptional control of adipogenesis, their gene expression 
profiles are distinct, and they do not share a direct common progenitor. Recent 
genetic studies using fat-mapping experiments have shown that while brown 
fat in the interscapular region and skeletal muscle share some common features 
and are derived from Myf5 expressing (Myf5+) cells (previously assumed to 
be exclusively present in committed skeletal muscle precursors), these Myf5+ 
precursor cells were absent in white and beige cells [12, 13]. Studies from sev-
eral other laboratories using global gene expression as well as mitochondrial 
proteomics signature confirmed that BAT is highly related to the skeletal muscle 
and not WAT [14, 15]. The divergence of brown adipocyte precursor and skeletal 
muscle was investigated using Pax7, another myogenic marker in pulse-chase 
experiments, and it was reported that this divergence occurred between embry-
onic day 9.5 and 11.5 in mice [16]. UCP1-expressing beige adipocytes present in 
epididymal WAT (Epi WAT) are thought to be derived through the proliferation 
and differentiation of platelet-derived growth factor receptor α (PDGRF α), 
CD44, and SC1 precursor cells [17]. Beige or brown-like cells in the inguinal 
WAT, on the other hand, are suggested to be derived from Myf5-negative 
(Myf5-) precursor cells [12]. However, this view has recently been challenged 
by various groups on the basis of linage analysis studies that suggest that subsets 
of white adipocytes are derived from both Myf5+ and Myf5- precursors and 
respond to beta-3 adrenergic receptor (β3-AR) signaling suggesting that these 
beige adipocytes may have multiple origins [18–20]. A subset of UCP1-positive 
beige adipocytes is also recently reported to arise from Myh11, selectively 
expressed in smooth muscle cells [21]. It is also possible that beige cells can 
either originate from mesodermal stem cells or trans-differentiation of mature 
white adipocytes [22]. Beige cells may also originate from Ebf2+ precursors 
located in the subcutaneous adipose tissue (SAT) population characterized by 
specific markers Cd137 and Tmeme26 [23]. Furthermore, it is also possible that 
thermogenic adipocytes may arise from endothelial cells and capillaries where 
retinoic acid (RA) could induce adipose browning by activating VEGF signal-
ing pathways [24]. RA is known to trigger angiogenesis and facilitate de novo 
generation of Pdgrfα expressing adipocyte precursors mediated via VEGFA/
VEGFR2 signaling [25]. These findings, therefore, collectively suggest that beige 
adipocytes which are composed of heterogeneous cell populations may have 
distinct cellular origins.
The acquisition of morphological and molecular features of brown and beige 
fat is under the control of PPARγ-coactivator 1α (PGC-1α) [26]. PGC-1α is induced 
early in brown fat differentiation and is preferentially expressed in mature brown 
adipocytes. PGC1-1α ectopic expression is sufficient to promote various aspects 
of differentiation toward the brown fat lineage. PGC-1α is also rapidly and highly 
induced by cold exposure and turns on several key components of the adaptive 
thermogenic program including fatty acid oxidation, mitochondrial biogenesis, 
and increased oxygen consumption [27]. The expression levels of 140kD zinc 
figure containing transcription factor called PR domain containing 16 (PRDM16) 
are very high in BAT compared to the visceral WAT and appear to play a major role 
in brown adipose/skeletal muscle fate determination [28]. Ectopic expression of 
PRDM16 in cultured mesenchymal cells including white preadipocytes induced 
a complete brown fat differentiation program and activation of key thermogenic 
(Ucp1, Pgc-1α, cidea, and elov3) genes and coactivates the transcriptional activity 
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of PGC-1α/PGC-1β, as well as PPARα and PPARγ [12, 28]. Coincident with these 
changes, PRDM16 expression also led to suppression of several white fat and 
muscle-selective markers [29]. On the other hand, genetic ablation of PRDM16 in 
brown fat leads to significant increase in white adipose and muscle-specific genes 
[28]. These findings, therefore, suggest that PRDM16 acts as a critical cell fate 
regulator of brown fat, and careful analysis of its embryonic expression pattern 
will be extremely valuable to dissect out the putative brown fat-skeletal muscle 
precursors. Signaling molecules that control the timing and specificity of PRDM16 
expression during development are unknown. Certain growth factors like bone 
morphogenetic proteins (BMPs), members of the TGF-β superfamily of secreted 
factors, are reported to influence both brown and white adipocyte differentiation 
[30–32]. While BMP2 and BMP4 are reported to promote white adipose cell differ-
entiation, BMP7 is reported to selectively induce brown adipogenesis in committed 
precursor cells [32, 33]. BMP7 exposure to fibroblast cultures results in induction of 
full brown fat differentiation program, including induction of PRDM16 and UCP1 
expression [30]. Importantly, significantly reduced amounts of BAT mass were 
observed in BMP7-deficient mice. However, it is not clear whether BMP7 plays any 
role in the regulation of PRDM16.
Under basal conditions both beige and brown adipocytes share some of the 
same key markers including UCP1 and PRDM16; however, data from clonal cell 
lines suggest that beige and brown adipose cells express related but  distinctly 
 different gene expression profiles [23]. Beige cells are highly enriched in 
Tmem26, Tbx1, and CD137 expression [23]. Comprehensive gene  expression 
analysis of adipose tissues isolated from interscapular BAT and inguinal fat 
revealed several other beige-selective genes including Ear2, Sp100, Klh113, 
and Slc27a [23]. Molecular profiling and histological analysis of human BAT 
identified additional beige-selective markers HoxC8, HoxC9, Cited1, and Shox2 
[34, 35]. On the other hand, classical brown adipocytes selectively express 
epithelial V-like antigen (Eva 1), Zic1, Lhx1, and Epsti [23, 36–38]. Using adipose 
tissues isolated from white and interscapular BAT from 129SVE mice, Wu et al. 
identified additional genes including Hspb7, Ebf3, Pdk4, Fbxo31, and Oplah that 
were enriched in BAT [23]. Using a combination of in silico, in vitro, as well 
as in vivo approaches, Ussar et al. reported the identification of three new cell 
 surface markers of adipose tissues [39]. In this study, amino acid transporter 
Asc1 was identified as a white adipocyte-specific cell surface protein with very 
low to undetectable levels in brown adipocytes, whereas amino acid transporter 
PAT2 and the purinergic receptor P2RX5 are cell surface markers expressed in 
classical brown and beige adipocytes.
Studies from microRNA (miRNA) signature analysis between beige and brown 
adipogenesis have provided significant differences in their molecular signature. 
MiRNA-193b-365 cluster is expressed in brown fat tissues and initially thought to 
be involved in the regulation of brown fat differentiation by inhibiting Runx1t1, 
which inhibits BAT differentiation [40]. However, subsequent in vivo studies 
show a normal BAT function in the absence of miRNA-193b-365 [41]. Inhibition of 
miRNA-182 and miRNA-203 in brown adipocytes led to downregulation of several 
genes involved in oxidative phosphorylation and electron transport [42]. Inhibition 
of miRNA-106b-93 led to induced expression of several adipogenic markers [43]. 
Similarly, positive (miRNA-196b) and negative (miRNA-26) regulation of beige 
adipogenesis have been identified [44, 45]. miRNAs that positively (miRNA-30 
family) and negatively (miRNA-27 and miRNA-34a) regulate both brown and 
beige adipocytes are also identified [46–48]. Thus, there appear to be clear differ-
ences between BAT and beige miRNA gene signature in mouse and human tissues 
and cells.
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3.  Role of transforming growth factor-β (TGF-β) superfamily in adipose 
browning and metabolic health
The TGF-β superfamily consists of more than 33 members including TGFβ1, 
TGFβ2, and TGFβ3, bone morphogenetic proteins (BMPs), growth differentiation 
factors (GDFs), and activins that play important roles in growth, development, and 
function of diverse cell types including adipocytes [49, 50]. These evolutionary highly 
conserved superfamily members transmit their signals via dual serine/threonine 
kinase receptors and transcription factors called Smads. TGF-β superfamily members 
control various aspects of adipocyte biology. Adipose tissues from obese mice were 
reported to express elevated levels of TGF-β [3]. The binding of TGF-β family to their 
membrane receptors could be somewhat promiscuous and may allow 7 type I and 
5 type II receptors to transduce signaling from these TGF-β superfamily members. 
Multiple cell types including adipose progenitors, preadipocytes, and adipocytes 
along with various immune cells are known to express protein belonging to TGF-β 
superfamily and their antagonists [51]. The role of TGF-β/Smad3 signaling in regulat-
ing beige adipocyte phenotype and metabolic characteristics were elegantly demon-
strated by Yadav et al. [4]. They observed significant positive correlation between 
TGF-β1 levels and adiposity in both rodents and human subjects. Using Smad3−/− 
mice, they provided interesting link between Smad3 loss and protection against 
diet-induced obesity and related metabolic syndromes. These changes in metabolic 
parameters were associated with induction of white to brown phenotype and signifi-
cantly increased mitochondrial biogenesis. In the same study, examination of a total 
of 184 nondiabetic human subjects from diverse ethnic groups, the authors identified 
direct relationship between circulating TGF-β1 levels and BMI, fat mass, and VO2 
consumption. Furthermore, anti-TGF-β antibody in Lepob/ob and diet-induced obesity 
mouse models resulted in significantly reduced body weight, improved glucose and 
insulin tolerance, as well as significantly reduced fasting glucose and insulin levels. 
These metabolic improvements were associated with elevated expression of BAT/
mitochondria-specific proteins in white adipose tissues. Such links between TGF-β 
signaling and mitochondrial energy metabolism pathway have also been reported by 
several other laboratories [52, 53]. Extracellular matrix protein microfibril-associated 
glycoprotein (MAGP) was found to be significantly altered in obese humans, and 
inactivation of MAGP1 gene (Mfap2−/−) resulted in adipocyte hypertrophy and 
predisposition to metabolic diseases. Mfap2−/− mice had significantly lower expres-
sion of UCP1 expression in BAT and display reduced subcutaneous adipose browning 
and defective adaptation to cold exposure [53]. Treatment of these Mfap2−/− mice 
with neutralizing concentrations of anti-TGF-β antibody led to decreased adiposity 
and improved body temperature. Administration of a novel activin receptor type II 
B (ActRIIB) decoy receptor containing the extracellular domain of ActRIIB fused to 
human Fc (ActRIIB-Fc) resulted in suppression of diet-induced obesity and associ-
ated metabolic functions in mice [54]. In the same study, significantly increased 
adipose browning in epididymal white fat displaying robustly increased expression 
of UCP1 and PGC 1-α was observed following ActRIIB-Fc treatment. Furthermore, 
protection from diet-induced obesity in ActRIIB-Fc-treated mice was demonstrated 
to result from increased energy expenditure and not decreased caloric intake. 
Combined together, these interesting findings suggest novel insights into the role of 
TGF-β signaling in suppressing adipose browning program within white fat tissues in 
both mouse models and human subjects suggesting that efficient blockade of TGF-β 
activity could serve as an effective treatment strategy for obesity and diabetes.
Myostatin (Mst) is a key member of the TGF-β superfamily which is known to 
play a major role in the regulation of skeletal muscle growth. However, recent stud-
ies have clearly indicated that the effect of Mst extends beyond its role in skeletal 
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muscle. Genetic deletion of Mst displays favorable changes in several metabolic 
parameters including decreased fat deposition, enhanced fatty acid oxidation, 
improved insulin sensitivity, and increased resistance to diet-induced obesity 
besides increased skeletal muscle mass [55, 56]. Since Mst is expressed at very low 
levels in adipose tissues [57], it remains unclear how depletion of Mst can sup-
press fat accumulation. Earlier studies by Kim et al. show that treatment of mouse 
primary brown preadipocytes with recombinant Mst led to significant inhibition 
of brown adipogenic differentiation and reduced expression of markers Ucp1, 
Prdm16, and Pgc-1α [58]. A comparison of key thermogenic markers obtained from 
epididymal (Epi) and subcutaneous (SC) white adipose tissues shows significantly 
increased expression of UCP1 and PRDM16 in Mst KO mice compared to the WT 
littermates [54]. Using differentiating primary cultures isolated from WT and Mst 
KO mouse embryonic fibroblasts (MEFs) in the same study, Braga et al. further 
confirmed upregulation of key thermogenic markers in Mst KO mice compared to 
the WT mice [5]. Furthermore, recombinant Mst protein treatment of the dif-
ferentiating MEFs significantly downregulated several key thermogenic markers 
including UCP1, PRDM16, PGC-1α/PGC-1β, and BMP7. Also, protein expression of 
adiponectin and phosphorylated AMP-activated protein kinase (pAMPK), which 
control the expression of genes involved in energy metabolism in coordination with 
NAD+-dependent sirtuin 1 (SirT1), were upregulated in Mst KO MEFs compared to 
the WT group [59, 60]. In another study, Chio et al. reported significantly increased 
energy expenditure and leptin sensitivity in Mst-deficient mice that could explain 
low fat mass in these mice compared to the WT group [61]. Shan et al. demonstrated 
that inhibition of Mst signaling in WAT SVF cells failed to induce browning of 
white adipocytes in vitro, suggesting that loss or inhibition of Mst signaling in pre-
adipocytes does not account for adipose browning in white adipocyte tissues in Mst 
KO mice [62]. In order to test the possible non-cell autonomous effects of Mst, the 
authors thoroughly analyzed various muscle-derived circulating factors that could 
account for the browning phenotype. They reported that skeletal muscle-derived 
Fndc5 (irisin) plays a central role in mediating white adipose browning in Mst KO 
mice via activation of AMPK-PGC1α-Fndc5 pathway, suggesting the involvement 
of muscle-adipose cross talk during the process [63, 64]. Fndc5/irisin was initially 
identified as a PGC-1α-dependent myokine that is responsible for adipose browning 
both in vitro and in vivo and protects diet-induced obesity in obesity [65]. Possible 
involvement of Fndc5 in mediating adipose browning in Mst loss-of-function 
models has emerged from other laboratories. Dong et al. also confirmed possible 
intermediate role for Fndc5/irisin-mediated adipose browning in Mst KO mice. In 
another study, Mst signaling was shown to regulate Fndc5 expression and adipose 
browning via upregulation of miRNA-34a. Several laboratories have demonstrated 
that the absence of Mst in both in vitro and in vivo models improves insulin sensi-
tivity [58, 66]. Several other laboratories provided additional evidence to support 
the view that Mst loss-of-function results in significant metabolic improvements 
resulting from adipose browning. Increased insulin sensitivity and WAT browning 
were reported in Meishan pigs with Mst functional deletion [67]. Several browning-
related genes including UCP1, PGC-1α, PRDM16, Cidea, CD137, and Tmem26 were 
significantly upregulated in these Mst-deficient pigs. Protein expression levels 
of insulin receptor (IR) and insulin receptor substrate (IRS) were significantly 
induced in the skeletal muscle of these Mst-deficient pigs. Interestingly, serum irisin 
levels and skeletal muscle protein expression of irisin precursor protein FNDC5 
were significantly higher in Mst-null pigs than wild-type pigs. These authors also 
demonstrated that inhibition of irisin expression was unable to block the activa-
tion of insulin signaling pathway, thus, implying that irisin may not be required 
for activation of insulin signaling in Mst-deficient skeletal muscle [67]. Genetic 
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disruption of Mst (Mst−/−) in LDLR−/− (Mst−/−/LDLR−/−) mice was shown to 
reduce the development of proatherogenic dyslipidemia, improve insulin-mediated 
glucose disposal, and protect against hepatic steatosis [68]. Furthermore, Guo et al. 
demonstrated that administration of adeno-associated virus 9 (AAV9)-mediated 
Mst-pro-peptide in adult LDLR−/− mice reduced diet-induced hepatosteatosis and 
progression of atherosclerosis [69]. In both these reports, the beneficial metabolic 
effects were claimed to result from enlarged muscle mass following inactivation 
of functional Mst in LDLR−/− mice. Several recent reports have provided strong 
evidence suggesting that brown fat activation could reduce hypercholesterolemia 
and protect from atherosclerosis development [70–72]. Therefore, it is possible that 
observed beneficial effects of Mst inactivation in LDLR−/− background could be 
mediated at least in part via adipose browning.
More recently, Mst expression has been linked to mediate BAT-muscle cross talk 
[73]. Induction of Mst following loss of interferon regulatory factor 4 (IRF4) in 
BAT leads to significantly reduced exercise capacity, ribosomal protein synthesis, 
and mitochondrial function [73]. On the other hand, reduced serum levels of Mst 
resulting from IRF4 overexpression significantly increased exercise capacity in 
muscle. IRF4 expression was found to be induced in brown adipocytes following 
cold exposure and β3-adrenergic receptor (AR) agonist [74]. IRF4 expression was 
reported to be sufficient to induce thermogenic program in BAT, and loss of IRF4 in 
brown fat leads to significantly reduced energy expenditure. Also, IRF4 was shown 
to physically and functionally interact with PGC-1α to upregulate transcription of 
Ucp1 gene and drive mitochondrial biogenesis and thermogenic program in BAT. In 
light of these exciting reports establishing IRF4 as a novel inhibitor of Mst, it is not 
surprising that IRF4 could antagonize the bioactivity of secreted Mst present in the 
blood to promote overall thermogenic program.
4. Follistatin regulation of white and brown adipose characteristics
Follistatin (Fst) is a soluble secreted glycoprotein that is known to bind and 
neutralize the activity of several members of the TGF-β superfamily including 
activins and Mst in a variety of cell lines [9–10, 77]. Several genetic studies have 
convincingly demonstrated an essential role of Fst in the regulation of muscle 
mass. Elegant initial studies led by Lee and McPherron demonstrated that inhibi-
tion of Mst either by genetic manipulation or overexpressing Fst resulted in signifi-
cantly increased muscle mass in mice [75]. The direct role for Fst in the regulation 
of muscle mass was also verified by several laboratories [8, 9, 76]. Fst was identi-
fied as a downstream target of testosterone during its pro-myogenic action in both 
in vitro and in vivo studies [8, 9]. Testosterone treatment of mouse mesenchymal 
multipotent C3H 10T1/C3H 10T2 cells led to upregulation of Fst and altered the 
expression of several key members of TGF-β superfamily [8]. Testosterone-
induced upregulation of key myogenic markers MyoD and myosin heavy chain II 
proteins in C3H 10T1/C3H 10 T2 cells was abolished in cells simultaneously treated 
with anti-Fst antibody, suggesting an essential role of Fst during testosterone regu-
lation of myogenic differentiation. The essential role of Fst was also established in 
in vivo studies using castrated male mice, where Fst gene expression level signifi-
cantly reduced in the levator ani (LA) muscle compared to the sham-operated male 
mice, but testosterone supplementation in castrated mice upregulated Fst mRNA 
expression in LA muscle to the baseline levels [8]. Subsequent studies by Braga 
et al. reported that primary culture of muscle satellite cells express Fst and respond 
to testosterone treatment. Fst blocked TGF-β-induced inhibition of MHC II expres-
sion and induction of Smad2/Smad3 phosphorylation in satellite cells [9]. These 
Adipose Tissue - An Update
8
reports provide conclusive evidence that Fst plays an important role in promoting 
myogenic differentiation and increasing muscle mass. In spite of several reports 
demonstrating as essential role of Fst in regulating muscle mass and its function, 
its role in lipid metabolism and energy balance was largely unknown. Fst-deficient 
mice die within hours after birth and have several defects including reduced size 
of diaphragm muscle [76]. These severe musculoskeletal defects were suggested 
to account for the neonatal death of these Fst-deficient pups. Since maintenance 
of body temperature through thermogenesis during early hours of neonatal life is 
extremely important, and both skeletal muscle and thermogenic brown fat share 
Myf5+ precursor cells, it is logical to test whether Fst could play a role in regulating 
the thermogenic program along with its established role in muscle development. 
Based on this logic and several published reports that Fst can bind and antagonize 
the biological actions of TGF-β/Mst signaling [8, 9], which are known inhibitors 
of thermogenic program, Braga et al. hypothesized that Fst may promote adipose 
browning and favorably alter energy metabolism [11]. Initial quantitative analysis 
of Fst gene expression in a mouse tissue panel consisting of several metabolic 
tissues demonstrated that Fst expression was highest in BAT along with skeletal 
muscle and was also expressed at a substantial level in inguinal WAT and the liver 
[11]. The expression levels in other tissues including the heart, intestine, and testis 
were significantly lower. This finding for the first time suggested a possible novel 
role of Fst in BAT and WAT and led to a series of subsequent in vitro and in vivo 
experimental approaches to delineate the precise role of Fst in adipose tissues of 
both origins. Using immortalized mouse brown preadipocytes, the authors clearly 
demonstrated that Fst protein expression was significantly induced in differenti-
ated BAT cells displaying characteristic multilocular lipid droplets compared to 
the undifferentiated cells [11]. As expected, levels of key brown adipose markers 
such as UCP1 and PRDM16 were also significantly induced after differentiation 
of BAT cells. Furthermore, Fst gene expression in BAT was dramatically induced 
following cold exposure of the mice, suggesting that Fst is a novel cold-inducible 
gene and could play important role in regulating key metabolic functions. Since 
Fst KO mice are not viable, Braga et al. utilized primary cultures of differentiat-
ing mouse embryonic fibroblast (MEF) cultures isolated from Fst KO and WT 
embryos to test whether Fst loss-of-function results in defective thermogenic 
program [11]. Significant impairment in adipogenic differentiation and upregula-
tion of BAT-specific markers were noted in Fst-deficient MEF cultures compared 
to the WT. Exogenous recombinant Fst protein treatment was able to rescue the 
thermogenic genes and proteins in Fst-deficient MEF cultures and further induced 
the expression of several BAT-specific genes in differentiated mouse BAT cells. 
Affymetrix global gene expression profiling clearly demonstrated lipid metabolism 
as the most significantly altered pathway and identified several genes involved 
in lipid metabolism and energy production such as Adn, Thrsp, Hp, Acsl1, Fabp4, 
Pparg, and Cd36 were significantly downregulated in Fst KO MEFs compared 
to the WT. Significantly lower basal mitochondrial respiration in Fst KO MEFs 
compared to the WT cultures was rescued by exogenous recombinant Fst, suggest-
ing that Fst increases cellular respiration [11].
In subsequent experiments, Singh et al. explored the in vivo actions of Fst over-
expression on both white and brown adipose tissues using Fst-transgenic (Fst-Tg) 
mice to determine whether Fst promotes adipose browning and brown adipose mass 
and function in these mice and identify possible molecular targets of Fst in these 
adipose tissues. Fst-Tg mice express Fst under a muscle-specific promoter [75] in 
which the circulating Fst levels are 1.5-fold higher along with ~70% increased inter-
scapular BAT mass compared to the WT mice [77]. BAT signature genes and several 
key proteins involved in mitochondrial biogenesis, fatty acid oxidation (FAO), 
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were significantly upregulated in iBAT as well as in Epi and SC adipose tissues of 
Fst-Tg mice compared to the WT mice [77]. The BAT marker UCP1 and beige-
specific markers CD137 were significantly higher in both WAT depots of Fst-Tg mice 
compared to WT, with relatively larger differences observed in SC adipose depots. 
Several other markers involved in mitochondrial biogenesis and FAO were also 
found to be induced in both adipose depots from Fst-Tg mice compared to the WT 
mice. These observed differences in adipose browning capacity between the two 
WAT depots were found to be consistent with previous reports [78].
The actions of Fst in regulating WAT and BAT adipose characteristics were 
shown to be mediated via two distinct mechanisms. Fst increased phosphorylation 
of p38 mitogen-activated protein kinase (p38 MAPK) and extracellular signal- 
regulated kinase (ERK1/ERK2) in both WAT depots, while it increased Myf5 
expression in iBAT of Fst-Tg mice [77]. The authors utilized in vitro studies to fur-
ther confirm the obligatory and mechanistic basis for these distinctly different Fst 
targets. In differentiating 3T3-L1 cells, recombinant Fst treatment led to significant 
induction of UCP1 and beige-specific marker CD137. Pharmacological inhibition of 
p38 MAPK and ERK1/ERK2 phosphorylation by SB023580 (10 μM) and PD98059 
(10 μM), respectively, either alone or in combination, led to significant blockade of 
Fst-induced (i) phosphorylation of both these proteins as expected and (ii) upregu-
lation of UCP1 protein [77]. On the other hand, in BAT and differentiated mouse 
BAT cells, Fst increased Myf5 protein expression. Knockdown of Myf5 expression 
led to significant inhibition of recombinant Fst-mediated increase in UCP1 protein 
expression in differentiated mouse BAT cells. Additionally, Fst treatment was able 
to rescue Myf5 gene and protein expression in Fst KO MEFs, reinforcing that Myf5 
is a critical mediator of Fst action in BAT [77]. Since BAT and skeletal muscle share 
Myf5-expressing progenitor cells [78, 79], the authors proposed that Fst promotes 
BAT activation and skeletal muscle growth by upregulating Myf5. Based on these 
novel findings, the authors proposed that Fst induces Myf5 expression in BAT 
and Myf5-positive progenitor cells to increase classical BAT activation, whereas 
it promotes phosphorylation of p38MAPK and ERK1/ERK2 in WAT to promote 
adipose browning. It is also possible that Fst could efficiently enhance the produc-
tion of one or more of several myokines which are shown to induce white adipose 
browning including irisin (encoded by Fndc5 gene), IL6, or FGF21 [80–82]. Both 
Fst and FGF21 were shown to be induced and secreted following exercise [81]. Also, 
secretion of irisin by skeletal muscle in response to exercise was reported to induce 
phosphorylation of p38 MAPK and ERK1/ERK2 leading to white adipose browning 
[80]. Upregulation of Fndc5 gene expression was reported in skeletal muscle after 
treatment with both recombinant Fst protein and anti-Mst antibody [62], suggest-
ing that Fst could target irisin/Mst-mediated pathway in muscle tissue to promote 
adipose browning mediated via muscle-adipose cross talk. Using similar MEF-based 
primary cultures obtained from WT and Fst KO and Mst KO, Braga et al. showed 
reciprocal regulation of BMP7 [5, 11], a key driver of brown adipogenesis and 
energy metabolism by Fst and Mst. These findings were confirmed by other labora-
tories in support of Fst-induced upregulation of BMP7 [83] and its downregulation 
by Mst [84]. Gene expression analysis of MEF primary cultures from WT and Fst 
KO versus WT and Mst KO shows several genes that were reciprocally regulated by 
Fst and Mst as identified by Affymetrix gene expression analysis and further vali-
dated by quantitative real-time PCR analysis (Figure 1). Analysis of basal oxygen 
consumption rate (OCR) in differentiated MEF cultures from these WT and Fst/
Mst KO groups further suggests reciprocal effects of Fst and Mst on mitochondrial 
respiration (Figure 2). Combined together, these findings support the view that 
Fst may exert its pro-browning effects at least in part by inhibiting Mst signaling. 
Follistatin-like-3 (FSTL3) has been reported as another Mst binding protein that 
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could play an important role in regulating fat mass and glucose homeostasis [85]. 
FSTL3 knockout mice display distinct phenotype including decreased fat mass and 
improved insulin sensitivity. However, it is not known whether FSTL3 regulates 
BAT mass and thermogenic activity, suggesting that the role of Fst may be more 
complicated [86].
Activation of p38MAPK pathway that promotes adipose browning by 
β3-adrenergic receptor (β3-AR) has been well documented [87, 88]. Since 
intraperitoneal injection of β3-AR agonist CL316,243 in Fst-Tg mice resulted in 
additive response to UCP1 levels in WAT and BAT compared to the WT mice, 
it is possible that β3-AR signaling could play an important role upstream of 
p38 MAPK pathway during Fst-induced adipose browning. More recently, 
elegant studies by Liu et al. demonstrated that inhibition of follicle-stimulating 
hormone (FSH) through a polyclonal antibody induced adipose browning and 
activated BAT and thermogenesis [89]. Since Fst was initially isolated from 
follicular fluid and found to inhibit secretion of FSH from anterior pituitary, 
this recent report further validates the identification of Fst as a novel inducer of 
adipose browning.
Figure 1. 
Reciprocal effects of Fst and Mst on several genes involved in lipid and energy metabolism. Primary cultures 
obtained from differentiating WT and Fst/Mst KO cells were analyzed by Affymetrix global gene profiling. (A) 
Van diagram showing 27 common genes that were reciprocally regulated by Fst and Mst. (B) Heat map showing 
differential expression of those 27 genes. (C) List of reciprocally regulated common genes. (D, E) Validation of 
Affymetrix data real-time PCR analysis. n = 3; *p ≤ 0.05; **p ≤ 0.01.
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5.  Metabolic profiling of Fst overexpression and relevance to metabolic 
diseases
In order to get better understanding of observed adipose browning and its 
metabolic consequences in Fst overexpressing in mice (Fst-Tg) as well as in 
differentiated 3T3-L1 (3T3-L1 Fst) preadipocyte, Singh et al. initially performed 
quantitative analysis of abdominal fat volume by CT scan, glucose clearance, and 
serum lipid profiles [90]. Fst-Tg mice displayed significant decrease in abdominal 
fat mass, increased glucose clearance, and significantly lower triglyceride (TG) 
and free fatty acid (FFA) levels compared to the WT control mice. A comparison 
of the overall lipidomic profiles using gas chromatography time-of-flight tech-
nology (GC TOF) shows a general reduction in diglycerides (DG), triglycerides 
(TG), ceramide (D42:0), fatty acids (FA), phosphatidylcholine (PC), phospha-
tidylethanolamine (PE), and lysophosphatidylethanolamines (LPE: 16.0) in Fst 
overexpressing 3T3-L1 (3T3-L1 Fst) cells compared to the basal 3T3-L1 cells after 
adipogenic differentiation (ref). On the other hand, a significant increase in 
several lysophosphatidylcholines (LPC) including LPC 16:0, LPC 18:0, and LPC 
18:1 was observed in 3T3-L1 Fst cells in comparison to 3T3-L1 cells. The decreased 
levels of several of these lipid metabolites observed in 3T3-L1 Fst cells are known 
contributors toward the development of obesity and related metabolic diseases 
[91, 92]. Increased levels of several of these LPCs following Fst overexpression 
also suggest a beneficial role for Fst as these LPCs are reported to be significantly 
reduced in obesity and type 2 diabetes [93, 94]. Comprehensive analysis of 
metabolites obtained from epi and SC adipose tissue between WT and Fst-Tg 
mice provided significant differences between metabolites involved in energy and 
Figure 2. 
Reciprocal effects of Fst (A, B) and Mst (C, D) on basal oxygen consumption rate (OCR) as analyzed by the 
seahorse bioscience XF24 extracellular flux analyzer. Data are expressed as mean +/− SEM. *p ≤ 0.05; **p ≤ 0.01.
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lipid metabolism of the groups. Several components of the Krebs cycle includ-
ing citrate, succinylcarnitine, and fumarate were significantly downregulated 
in Fst-Tg Epi tissues compared to the WT tissues, whereas only reduced levels 
of succinate were found in SC adipose tissues form Fst-Tg mice compared to the 
WT mice. Also, several long-chain FAs, components of the carnitine metabolism, 
glycerolipids, ketone bodies, and lysolipids were selectively found to be lower in 
Fst-Tg Epi tissues than the WT group. Interestingly, levels of Epi cholesterol levels 
were also selectively reduced in Epi tissues only. Several key amino acids including 
tyrosine, components of tryptophan, branched-chain amino acid (BCAA), and 
urea cycle metabolism were also found to be dramatically reduced in Epi adipose 
tissues in Fst-Tg mice compared to the WT mice. A comparison of omega-3 
polyunsaturated fatty acid (ω-3 PUFAs) levels between the groups shows highly 
significant increase selectively in SC adipose tissues of Fst-Tg mice. Interestingly, 
ω-3 PUFAs are reported to improve not only obesity-associated metabolic dis-
orders including insulin resistance and dyslipidemia but also several aspects of 
energy and lipid metabolism and inflammation [95–97]. Significantly decreased 
levels of beta-hydroxybutyric acid (BHBA), the end product of FA beta-oxidation 
and key contributor to metabolic syndrome, were also observed in the Epi adipose 
tissues of Fst-Tg mice compared to the WT. Combined together, these compre-
hensive metabolomic profilings of Fst in vitro and in vivo overexpression show a 
clear pattern of favorable changes in several metabolites implicated in metabolic 
complications and provide future impetus to thoroughly investigate the novel 
therapeutic role of Fst.
6. Conclusions
Several lines of evidence support the view that brown and beige adipocytes play 
important roles in regulating various aspects of lipid and glucose metabolism. The 
browning process in WAT that entails a shift in WAT primary function from storing 
excess energy to the dissipation of energy has been linked to the prevention of pro-
gression and development of obesity and related metabolic abnormalities including 
insulin resistance, hyperlipidemia, and type 2 diabetes. Data generated from several 
laboratories collectively suggest that blocking of TGF-β/Smad3/Mst signaling 
efficiently increases brown adipose phenotypic and metabolic characteristics and 
possible downstream mediators during the process as summarized in Figure 3.
Accordingly, new strategies to identify and develop novel TGF-β/Mst inhibitors 
to increase BAT and beige adipose mass and activities are currently being explored 
with the hope that blockade of this signaling pathway could lead to the development 
of therapeutic avenues. Since Fst has been demonstrated to efficiently antagonize 
Mst and inhibit overall TGF-β signaling in several in vitro and in vivo models, the 
novel therapeutic potential of Fst for the treatment of obesity and related metabolic 
diseases needs to be thoroughly explored in preclinical studies. It is, therefore, 
necessary to identify the key molecular and cellular targets of Fst responsible for 
its regulation of overall thermogenic program. Although phosphorylation and 
activation of the p38MAPK/ERK1/ERK2 signaling by Fst in WAT have recently 
been linked to Fst-induced browning, the possible intermediate role of irisin during 
the process could not be ruled out. Similar to Fst, secretion of irisin by skeletal 
muscle is induced following exercise which could induce p38MAPK/ERK1/ERK2 
phosphorylation and lead to browning of WAT [80]. Fibroblast growth factor 21 
(FGF21), another exercise-induced secretory protein linked to adipose brown-
ing and which promotes brown adipose characteristics, has also been shown to 
be influenced by recombinant Fst (rFst) treatment in 3T3-L1 as well as in WAT of 
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Fst-transgenic (Fst-Tg) mice. Robust upregulation of FGF21/adiponectin/AMPK 
signaling pathway observed under both conditions suggests a possible mechanistic 
link between Fst and FGF21. Preclinical studies using an alternatively spliced cDNA 
of follistatin (FS344) delivered by adeno-associated virus (AAV) to muscle in both 
human patients with certain degenerative muscle disorders [98, 99] and nonhuman 
primates [100] show no apparent structural or functional aberrations in a variety of 
organs, suggesting the potential of Fst use in clinical trials, although these studies 
did not assess adipose tissue metabolic parameters. Therefore, novel antagonists 
of TGF-β/Mst signaling pathways, including Fst [101], hold a great promise for the 
treatment of not only muscle loss and dysfunction but also for obesity and related 
metabolic diseases.
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